Key insights to understand the immunogenicity of FVIII products

Jenny Goudemand; Flora Peyvandi; Sébastien Lacroix-Desmazes

doi:10.1160/TH16-01-0048

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2016; 116(S 01): S2-S9
DOI: 10.1160/TH16-01-0048

5th International Coagulation Meeting 2015 – Barcelona, Spain

Schattauer GmbH

Key insights to understand the immunogenicity of FVIII products

Jenny Goudemand

¹School of Medicine, University of Lille, Lille, France

,

Flora Peyvandi

²Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico and University of Milan, Italy

,

Sébastien Lacroix-Desmazes

³INSERM UMR S 1138, Centre de Recherche des Cordeliers, Paris, France

› Institutsangaben

Abstract

Summary

The treatment of haemophilia has made significant progress in recent decades, and patients are now being treated safely with great clotting products. However, inhibitor development remains the largest problem, particularly in children. Consequently, the haemostasis that was obtained with traditional clotting factors is not being achieved. Moreover, inhibitor complications translate into adult life and there are an increasing number of situations where adult patients with an inhibitor require major surgery but the clinician is faced with the knowledge that required haemostasis levels are difficult to achieve. Therefore, it is of upmost importance to consider factors relating to inhibitor development, and to determine how inhibitors can be prevented and/or eliminated. Of the various factors at play with regard to inhibitor development, it is important to consider the immunogenicity of factor VIII (FVIII) products, and this topic is the focus of the current paper.

Keywords

Haemophilia - FVIII concentrates - immunogenicity - inhibitor - von Willebrand factor

Volltext

Referenzen

References
1 Carcao M, Re W, Ewenstein B. The role of previously untreated patient studies in understanding the development of FVIII inhibitors. Haemophilia. 2015 Epub ahead of print.
2 Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A: a systematic review. Haemophilia 2003; 09: 418-435.
3 Gouw SC, van der Bom JG, Ljung R. et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-239.
4 Calvez T, Chambost H, Claeyssens-Donadel S. et al. Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A. Blood 2014; 124: 3398-3408.
5 Collins PW, Palmer BP, Chalmers EA. et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000–2011. Blood 2014; 124: 3389-3397.
6 Vézina C, Carcao M, Infante-Rivard C. et al. Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010. Haemophilia 2014; 20: 771-776.
7 Fischer K, Lassila R, Peyvandi F. et al. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost 2015; 113: 968-975.
8 Berntorp E, Iorio A. Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. Blood 2015; 125: 3816-3817.
9 Calvez T, Chambost H, Lutz P. et al. Response: Confounding by indication is unlikely to explain the higher inhibitor incidence in boys treated with a recombinant FVIII product. Blood 2015; 125: 3817-3819.
10 Haute SantéAutorité. Available from: http://www.has-sante.fr Accessed November 17, 2015
11 Gouw SC, van der Bom JG, Marijke van den Berg H. Treatment-related risk factors of inhibitor development in previously untreated patients with hemophilia A: the CANAL cohort study. Blood 2007; 109: 4648-4654.
12 Goudemand J, Rothschild C, d’Oiron R. et al. Plasma-derived factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A: report of the FranceCoag Network. J Thromb Haemost 2015; 13 (Suppl S2): 147 (Abstract OR143).
13 Astermark J. Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors. Haemophilia 2006; 12 (Suppl. 06) 8-13.
14 Gouw SC, van den Berg HM. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment. Semin Thromb Hemost 2009; 35: 723-734.
15 Kruse-Jarres R. Inhibitors: our greatest challenge. Can we minimize the incidence?. Haemophilia 2013; 19 (Suppl. 01) 2-7.
16 Gouw SC, van den Berg HM, Oldenburg J. et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 2012; 119: 2922-2934.
17 Hay CR, Oillier W, Pepper L. et al. HLA class II profile: a weak determinant of factor VIII inhibitor development in severe haemophilia A. UKHCDO Inhibitor Working Party. Thromb Haemost 1997; 77: 234-237.
18 Astermark J, Oldenburg J, Pavlova A. et al. Polymorphisms in the IL10 but not in the ILlbeta and IL4 genes are associated with inhibitor development in patients with hemophilia A. Blood 2006; 107: 3167-3172.
19 Astermark J, Oldenburg J, Carlson J. et al. Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A. Blood 2006; 108: 3739-3745.
20 Astermark J, Wang X, Oldenburg J. et al. Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A. J Thromb Haemost 2007; 05: 263-265.
21 Lozier JN, Rosenberg PS, Goedert JJ. et al. A case-control study reveals immunoregulatory gene haplotypes that influence inhibitor risk in severe haemophilia A. Haemophilia 2011; 17: 641-649.
22 Astermark J, Donfield SM, Gomperts ED. et al. The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Blood 2013; 121: 1446-1454.
23 Repessé Y, Peyron I, Dimitrov JD. et al. Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter. Haematologica 2013; 98: 1650-1655.
24 Eckhardt CL, Astermark J, Nagelkerke SQ. et al. The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A. J Thromb Haemost 2014; 12: 1294-1301.
25 Scharrer I, Bray GL, Neutzling O. Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates. Haemophilia 1999; 05: 145-154.
26 Viel KR, Ameri A, Abshire TC. et al. Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med 2009; 360: 1618-1627.
27 Lochan A, Macaulay S, Chen WC. et al. Genetic factors influencing inhibitor development in a cohort of South African haemophilia A patients. Haemophilia 2014; 20: 687-692.
28 Gunasekera D, Ettinger RA, Nakaya SFletcher. et al. Factor VIII gene variants and inhibitor risk in African American hemophilia A patients. Blood 2015; 126: 895-904.
29 Lorenzo JI, López A, Altisent C. et al. Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age. Br J Haematol 2001; 113: 600-603.
30 Santagostino E, Mancuso ME, Rocino A. et al. Environmental risk factors for inhibitor development in children with haemophilia A: a case-control study. Br J Haematol 2005; 130: 422-427.
31 Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. Semin Thromb Hemost 2013; 39: 740-751.
32 Oldenburg J, Lacroix-Desmazes S, Lillicrap D. Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity. Haematologica 2015; 100: 149-156.
33 Walsh G, Jefferis R. Post-translational modifications in the context of therapeutic proteins. Nat Biotechnol 2006; 24: 1241-1252.
34 Kannicht C, Ramström M, Kohla G. et al. Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII. Thromb Res 2013; 131: 78-88.
35 Mannucci PM, Garagiola I. Factor VIII products in haemophilia A: one size fits all?. Thromb Haemost 2015; 113: 911-914.
36 Calvez T, Laurian Y, Goudemand J. Inhibitor incidence with recombinant vs plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogeneous results from four published observational studies. J Thromb Haemost 2008; 06: 390-392.
37 Gouw SC, van der Bom IG, Auerswald G. et al. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-4697.
38 Iorio A, Halimeh S, Holzhauer S. et al. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma-derived or recombinant factor VIII concentrates: a systematic review. J Thromb Haemost 2010; 08: 1256-1265.
39 Franchini M, Coppola A, Rocino A. et al. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia a: a 2013 update. Semin Thromb Hemost 2013; 39: 752-766.
40 Mannucci PM, Gringeri A, Peyvandi F. et al. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl. 05) 65-68.
41 Peyvandi F, Mannucci PM, Garagiola I. et al. A randomized trial of factor VIII and neutralizing antibodies in hemophilia A. N Engl J Med 2016; 374: 2054-2064.
42 Lacroix-Desmazes S, Repessé Y, Kaveri SV. et al. The role of VWF in the immunogenicity of FVIII. Thromb Res 2008; 122 (Suppl. 02) S3-S6.
43 Kreuz W. The role of VWF for the success of immune tolerance induction. Thromb Res 2008; 122 (Suppl. 02) S7-S12.
44 Goudemand J, Rothschild C, Demiguel V. et al. Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A. Blood 2006; 107: 46-51.
45 Chalmers EA, Brown SA, Keeling D. et al. Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A. Haemophilia 2007; 13: 149-155.
46 Behrmann M, Pasi J, Saint-Remy JM. et al. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model. Thromb Haemost 2002; 88: 221-229.
47 Delignat S, Dasgupta S, André S. et al. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A. Haematologica 2007; 92: 1423-1426.
48 Kallas A, Kuuse S, Maimets T. et al. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice. Thromb Res 2007; 120: 911-919.
49 Qadura M, Waters B, Burnett E. et al. Recombinant and plasma-derived factor VIII products induce distinct splenic cytokine microenvironments in hemophilia A mice. Blood 2009; 114: 871-880.
50 Delignat S, Repessé Y, Navarrete AM. et al. Immunoprotective effect of von Willebrand factor towards therapeutic factor VIII in experimental haemophilia A. Haemophilia 2012; 18: 248-254.
51 Dasgupta S, Repessé Y, Bayry J. et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-612.
52 van Schooten CJ, Shahbazi S, Groot E. et al. Macrophages contribute to the cellular uptake of von Willebrand factor and factor VIII in vivo. Blood 2008; 112: 1704-1712.
53 Herczenik E, van Haren SD, Wroblewska A. et al. Uptake of blood coagulation factor VIII by dendritic cells is mediated via its CI domain. J Allergy Clin Immunol 2012; 129: 501-509 509.el-e5.
54 Castro-Núñez L, Dienava-Verdoold I, Herczenik E. et al. Shear stress is required for the endocytic uptake of the factor Vlll-von Willebrand factor complex by macrophages. J Thromb Haemost 2012; 10: 1929-1937.
55 Dasgupta S, Navarrete AM, André S. et al. Factor VIII bypasses CD91/LRP for endocytosis by dendritic cells leading to T-cell activation. Haematologica 2008; 93: 83-89.
56 Shen BW, Spiegel PC, Chang CH. et al. The tertiary structure and domain o rganization of coagulation factor VIII. Blood 2008; 111: 1240-1247.
57 Dasgupta S, Navarrete AM, Bayry J. et al. A role for exposed mannosylations in presentation of human therapeutic self-proteins to CD4+ T lymphocytes. Proc Natl Acad Sci USA 2007; 104: 8965-8970.
58 Bloem E, van den Biggelaar M, Wroblewska A. et al. Factor VIII C1 domain spikes 2092–2093 and 2158–2159 comprise regions that modulate cofactor function and cellular uptake. J Biol Chem 2013; 288: 29670-29679.
59 Wroblewska A, Reipert BM, Pratt KP. et al. Dangerous liaisons: how the immune system deals with factor VIII. J Thromb Haemost 2013; 11: 47-55.
60 Wroblewska A, van Haren SD, Herczenik E. et al. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood 2012; 119: 5294-5300.
61 Pratt KP, Shen BW, Takeshima K. et al. Structure of the C2 domain of human factor VIII at 1.5 A resolution. Nature 1999; 402: 439-442.
62 Arai M, Scandella D, Hoyer LW. Molecular basis of factor VIII inhibition by human antibodies. Antibodies that bind to the factor VIII light chain prevent the interaction of factor VIII with phospholipid. J Clin Invest 1989; 83: 1978-1984.
63 Meeks SL, Healey JF, Parker ET. et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
64 Jacquemin MG, Desqueper BG, Benhida A. et al. Mechanism and kinetics of factor VIII inactivation: study with an IgG4 monoclonal antibody derived from a hemophilia A patient with inhibitor. Blood 1998; 92: 496-506.
65 Leyte A, van Schijndel HB, Niehrs C. et al. Sulfation of Tyr1680 of human blood coagulation factor VIII is essential for the interaction of factor VIII with von Willebrand factor. J Biol Chem 1991; 266: 740-746.